200. Association of Podometrics Findings in Patients With Hypertension and Type 2 Diabetes: A Retrospective Analysis. Hypertension 2025 (in press) (IF 7.2) (IF 3.336)
Paschen C, Koeller MC, Schachner H, Nackenhorst M, Kläger J, Oszwald A, Dörr K, Kammer M, Kozakowski N, Rees A, Kain R, Hecking M, Oberbauer R, Regele H
199. Association of urinary EGF, FABP3, and VCAM1 levels with the progression of early diabetic kidney disease. Kidney Blood Press Res 2024, 49(1):1013-1025 (IF 2.3)
Keller F, Denicolò S, Leierer J, Kruus M, Heinzel A, Kammer M, Ju W, Nair V, Burdet F, Ibberson M, Menon R, Otto E, Choi YJ, Pyle L, Ladd P, Bjornstad PM, Eder S, Rosivall L, Mark PB, Wiecek A, Heerspink HJL, Kretzler M, Oberbauer R, Mayer G, Perco P.
198. Cilgavimab and Tixagevimab as pre-exposure prophylaxis in vaccine non-responder kidney transplant recipients during a period of prevalent SARS-CoV-2 BA.2 and BA.4/5 variants – a prospective cohort study (RESCUE-TX). EBioMedicine 2024, 109:105417 (IF 9.7)
Reindl-Schwaighofer R, Heinzel A, Raab L, Strassl R, Herz CT, Regele F, Doberer K, Helk O, Spechtl P, Aschauer C, Hu K, Jagoditsch R, Reiskopf B, Böhmig GA, Benka B, Mahr B, Stiasny K, Weseslindtner L, Kammer M, Wekerle T, Oberbauer R.
197. Initial empirical antibiotic therapy in kidney transplant recipients with pyelonephritis: A global survey of current practice and opinions across 19 countries on six continents. Transpl Infect Dis 2024, 26(6):e14362 (IF 2.6)
Coussement J, Bansal SB, Scemla A, Svensson MHS, Barcan LA, Smibert OC, Clemente WT, Lopez-Medrano F, Hoffman T, Maggiore U, Catalano C, Hilbrands L, Manuel O, DU Toit T, Shern TKY, Chowdhury N, Viklicky O, Oberbauer R, Markowicz S, Kaminski H, Lafaurie M, Pierrotti LC, Cerqueira TL, Yahav D, Kamar N, Kotton CN
196. Combination cell therapy leads to clonal deletion of donor-specific T cells in kidney transplant recipients. EBioMedicine 2024, 106:105239 (IF 9.7)
David AF, Heinzel A, Kammer M, Aschauer C, Reindl-Schwaighofer R, Hu K, Chen HS, Muckenhuber M, Kubetz A, Weijler AM, Worel N, Edinger M, Berlakovich G, Lion T, Sykes M, Wekerle T, Oberbauer R
195. Fluid management for sepsis-induced hypotension in patients with advanced chronic kidney disease: a secondary analysis of the CLOVERS trial. Crit Care 2024, 28(1):231 (IF 8.8)
Jorda A, Douglas IS, Staudinger T, Heinz G, Bergmann F, Oberbauer R, Sengölge G, Zeitlinger M, Jilma B, Shapiro NI, Gelbenegger G
194. 2-Step-Scores with optional nephropathology for the prediction of adverse outcomes for brain-dead donor kidneys in Eurotransplant. Nephrol Dial Transplant 2024, 40(1):83-108 (IF 4.8)
Ernst A, Regele H, Chatzikyrkou C, Dendooven A, Turkevi-Nagy S, Tieken I, Oberbauer R, Reindl-Schwaighofer R, Abramowicz D, Hellemans R, Massart A, Ljubanovic DG, Senjug P, Maksimovic B, Aßfalg V, Neretljak I, Schleicher C, Clahsen-van Groningen M, Kojc N, Ellis CL, Kurschat CE, Lukomski L, Stippel D, Ströhlein M, Scurt FG, Roelofs JJ, Kers J, Harth A, Jungck C, Eccher A, Prütz I, Hellmich M, Vasuri F, Malvi D, Arns W, Becker JU.
193. Early progression of chronic histologic lesions in kidney transplant biopsies is not associated with HLA histocompatibility. Nephrol Dial Transplant. Nephrol Dial Transplant 2024, 39(5):808-817
Jabbour R, Heinzel A, Reindl-Schwaighofer R, Gregorich MG, Regele H, Kozakowski N, Kläger J, Fischer G, Kainz A, Becker JU, Wiebe C, Oberbauer R.
192. A pan-tissue survey of mosaic chromosomal alterations in 948 individuals. Nat Genet 2023, 55(11):1901-1911 (IF 30.8)
Gao T, Kastriti ME, Ljungström V, Heinzel A, Tischler AS, Oberbauer R, Loh PR, Adameyko I, Park PJ, Kharchenko PV.
191. Renin-angiotensin system inhibitor discontinuation in COVID-19 did not modify systemic ACE2 in a randomized controlled trial. iScience 2023, 26(11):108146 (IF 5.8)
Rathkolb V, Traugott MT, Heinzel A, Poglitsch M, Aberle J, Eskandary F, Abrahamowicz A, Mueller M, Knollmueller P, Shoumariyeh T, Stuflesser J, Seeber I, Gibas G, Mayfurth H, Tinhof V, Schmoelz L, Zeitlinger M, Schoergenhofer C, Jilma B, Genser B, Hoepler W, Omid S, Karolyi M, Wenisch C, Oberbauer R, Zoufaly A, Hecking M, Reindl-Schwaighofer R.
190. Prospective assessment of pre-existing and de novo anti-HLA IgE in kidney, liver, lung and heart transplantation. Front Immunol 2023, 14:1179036
Mucha J, Cho A, Weijler AM, Muckenhuber M, Hofmann AG, Wahrmann M, Heinzel A, Linhart B, Gattinger P, Valenta R, Berlakovich G, Zuckermann A, Jaksch P, Oberbauer R, Wekerle T.
189. Monitoring of Sotrovimab-Levels as Pre-Exposure Prophylaxis in Kidney Transplant Recipients Not Responding to SARS-CoV-2 Vaccines. Viruses 2023, 15(8):1624 (IF 4.7)
Aschauer C, Heinzel A, Stiasny K, Borsodi C, Hu K, Koholka J, Winnicki W, Kainz A, Haslacher H, Oberbauer R, Reindl-Schwaighofer R, Weseslindtner L.
188. Sex differences in the survival benefit of kidney transplantation: a retrospective cohort study using target trial emulation. Nephrol Dial Transplant 2023, 39(1):36-44 (IF 4.8)
Geroldinger A, Strohmaier S, Kammer M, Wallisch C, Heinze G, Oberbauer R, Haller MC.
187. A paired-kidney allocation study found superior survival with HLA-DR compatible kidney transplants in the Eurotransplant Senior Program. Kidney Int 2023, 104(3):552-561
de Fijter JW, Dreyer GJ, Mallat MJ, Budde K, Pratschke J, Klempnauer J, Zeier M, Arns W, Hugo C, Rump LC, Hauser I, Schenker P, Schiffer M, Grimm MO, Kliem V, Olbricht CJ, Pisarski P, Banas B, Suwelack B, Hakenberg O, Berlakovich G, Schneeberger S, van de Wetering J, Berger SP, Bemelman F, Kuypers D, Heidt S, Rahmel A, Claas F, Peeters P, Oberbauer R, Heemann U, Krämer BK.
186. Cardiovascular Outcomes in De Novo Kidney Transplant Recipients Receiving Everolimus and Reduced Calcineurin Inhibitor or Standard Triple Therapy: 24-month Post Hoc Analysis From TRANSFORM Study.Transplantation 2023, 107(7):1593-1604. (IF 5.3)
Sommerer C, Legendre C, Citterio F, Watarai Y, Oberbauer R, Basic-Jukic N, Han J, Gawai A, Bernhardt P, Chadban S.
185. Development and Validation of a Prediction Model for Future Estimated Glomerular Filtration Rate in People With Type 2 Diabetes and Chronic Kidney Disease. JAMA Netw Open 2023, 6(4):e231870 (IF 13.8)
Gregorich M, Kammer M, Heinzel A, Böger C, Eckardt KU, Heerspink HL, Jung B, Mayer G, Meiselbach H, Schmid M, Schultheiss UT, Heinze G, Oberbauer R; BEAt-DKD Consortium
184. Different roles of protein biomarkers predicting eGFR trajectories in people with chronic kidney disease and diabetes mellitus: a nationwide retrospective cohort study. Cardiovasc Diabetol 2023, 22(1):74. (IF 8.949)
Kammer M, Heinzel A, Hu K, Meiselbach H, Gregorich M, Busch M, Duffin KL, Gomez MF, Eckardt KU, Oberbauer R; BEAt-DKD consortium
183. Optimum timing of antithymocyte globulin in relation to adoptive regulatory T cell therapy. Am J Transplant 2023, 23(1):84-92.
Muckenhuber M, Mucha J, Mengrelis K, How C, Reindl-Schwaighofer R, Heinzel A, Kainz V, Worel N, Berlakovich G, Edinger M, Oberbauer R, Wekerle T.
182. The systemic renin-angiotensin system in COVID-19. Sci Rep 2022, 12(1):20117
Reindl-Schwaighofer R, Hödlmoser S, Domenig O, Krenn K, Eskandary F, Krenn S, Schörgenhofer C, Rumpf B, Karolyi M, Traugott MT, Abrahamowicz A, Tinhof V, Mayfurth H, Rathkolb V, Mußnig S, Schmölz L, Ullrich R, Heinzel A, König F, Binder C, Bonderman D, Strassl R, Puchhammer-Stöckl E, Gorkiewicz G, Aberle JH, Jilma B, Wenisch C, Poglitsch M, Oberbauer R, Zoufaly A, Hecking M.
181. Development and validation of multivariable prediction models of serological response to SARS-CoV-2 vaccination in kidney transplant recipients. Front Immunol 2022, 13:997343
Osmanodja B, Stegbauer J, Kantauskaite M, Rump LC, Heinzel A, Reindl-Schwaighofer R, Oberbauer R, Benotmane I, Caillard S, Masset C, Kerleau C, Blancho G, Budde K, Grunow F, Mikhailov M, Schrezenmeier E, Ronicke S.
180. Survival Benefit of First Single-Organ Deceased Donor Kidney Transplantation Compared With Long-term Dialysis Across Ages in Transplant-Eligible Patients With Kidney Failure. JAMA Netw Open. 2022, 5(10):e2234971 (IF 13.8)
Strohmaier S, Wallisch C, Kammer M, Geroldinger A, Heinze G, Oberbauer R, Haller MC.
179. Bone Specific Alkaline Phosphatase and Serum Calcification Propensity Are Not Influenced by Etelcalcetide vs. Alfacalcidol Treatment, and Only Bone Specific Alkaline Phosphatase Is Correlated With Fibroblast Growth Factor 23: Sub-Analysis Results of the ETACAR-HD Study. Front Med (Lausanne). 2022, 9:948177 (IF 3.1)
Dörr K, Hödlmoser S, Kammer M, Reindl-Schwaighofer R, Lorenz M, Reiskopf B, Jagoditsch R, Marculescu R, Oberbauer R.
178. Stopping of Mycophenolic Acid in Kidney Transplant Recipients for 2 Weeks Peri-Vaccination Does Not Increase Response to SARS-CoV-2 Vaccination-A Non-randomized, Controlled Pilot Study. Front Med (Lausanne) 2022, 9:914424 (IF 3.1)
Regele F, Heinzel A, Hu K, Raab L, Eskandary F, Faé I, Zelzer S, Böhmig GA, Bond G, Fischer G, Oberbauer R, Reindl-Schwaighofer R.
177. The Effect of FGF23 on Cardiac Hypertrophy Is Not Mediated by Systemic Renin-Angiotensin- Aldosterone System in Hemodialysis. Front Med (Lausanne) 2022, 9:878730 (IF 3.1)
Dörr K, Kammer M, Reindl-Schwaighofer R, Lorenz M, Marculescu R, Poglitsch M, Beitzke D, Oberbauer R
176. Effects of Reduced-Dose Anti-Human T-Lymphocyte Globulin on Overall and Donor-Specific T-Cell Repertoire Reconstitution in Sensitized Kidney Transplant Recipients. Front Immunol 2022, 13:843452 (IF 7.3)
Aschauer C, Jelencsics K, Hu K, Gregorich M, Reindl-Schwaighofer R, Wenda S, Wekerle T, Heinzel A, Oberbauer R.
175. Nephrologists’ Perspectives on Gender Disparities in CKD and Dialysis. Kidney Int Rep 2021 Nov 9;7(3):424-435 (IF 6)
Tong A, Evangelidis N, Kurnikowski A, Lewandowski M, Bretschneider P, Oberbauer R, Baumgart A, Scholes-Robertson N, Stamm T, Carrero JJ, Pecoits-Filho R, Hecking M.
174. Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients: A Randomized Clinical Trial. JAMA Intern Med. 2022, 182(2):165-171 (IF 22.5)
Reindl-Schwaighofer R, Heinzel A, Mayrdorfer M, Jabbour R, Hofbauer TM, Merrelaar A, Eder M, Regele F, Doberer K, Spechtl P, Aschauer C, Koblischke M, Paschen C, Eskandary F, Hu K, Öhler B, Bhandal A, Kleibenböck S, Jagoditsch RI, Reiskopf B, Heger F, Bond G, Böhmig GA, Strassl R, Weseslindtner L, Indra A, Aberle JH, Binder M, Oberbauer R
173. ImmunoDataAnalyzer: a bioinformatics pipeline for processing barcoded and UMI tagged immunological NGS data. BMC Bioinformatics 2022, 23(1):21 (IF 2.9)
Vetter J, Schaller S, Heinzel A, Aschauer C, Reindl-Schwaighofer R, Jelencsics K, Hu K, Oberbauer R, Winkler SM
172. Dynamic prediction of renal survival among deeply phenotyped kidney transplant recipients using artificial intelligence: an observational, international, multicohort study. Lancet Digit Health 2021, S2589-7500(21):00209-0. (IF 23.8)
Raynaud M, Aubert O, Divard G, Reese PP, Kamar N, Yoo D, Chin CS, Bailly É, Buchler M, Ladrière M, Le Quintrec M, Delahousse M, Juric I, Basic-Jukic N, Crespo M, Silva HT Jr, Linhares K, Ribeiro de Castro MC, Soler Pujol G, Empana JP, Ulloa C, Akalin E, Böhmig G, Huang E, Stegall MD, Bentall AJ, Montgomery RA, Jordan SC, Oberbauer R, Segev DL, Friedewald JJ, Jouven X, Legendre C, Lefaucheur C, Loupy A
171. Estimation of the prevalence of chronic kidney disease in people with diabetes by combining information from multiple routine data collections. The Journal of the Royal Statistical Society, Series A (Statistics in Society) 2021, 184:1260-1282. (IF 2.175)
Geroldinger A, Hronsky M, Endel F, Endel G, Oberbauer R, Heinze G
170. Waiting Time for Second Kidney Transplantation and Mortality. CJASN 2022, 17(1):90-97 (IF 8.5)
Kainz A, Kammer M, Reindl-Schwaighofer R, Strohmaier S, Petr V, Viklicky O, Abramowicz D, Naik M, Mayer G, Oberbauer R
169. Prospective tracking of donor-reactive T-cell clones in the circulation and rejecting human kidney allografts. Frontiers in Immunology 2021, 12:750005 (IF 7.3)
Aschauer C, Jelencsics K, Hu K, Heinzel A, Gloria M, Vetter J, Schaller S, Winkler S, Weinberger J, Pimenov L, Gualdoni GA, Eder M, Kainz A, Regina A, Regele H, Reindl-Schwaighofer R, Wekerle T, Bernhard J, Sykes M, Oberbauer R
168. Recurrence of IgA Nephropathy after Kidney Transplantation in Adults. Clin J Am Soc Nephrol. 2021, 16(8):1247-1255. (IF 8.5)
Uffing A, Pérez-Saéz MJ, Jouve T, Bugnazet M, Malvezzi P, Muhsin SA, Lafargue MC, Reindl-Schwaighofer R, Morlock A, Oberbauer R, Buxeda A, Burballa C, Pascual J, von Moos S, Seeger H, La Manna G, Comai G, Bini C, Russo LS, Farouk S, Nissaisorakarn P, Patel H, Agrawal N, Mastroianni-Kirsztajn G, Mansur J, Tedesco-Silva H, Ventura CG, Agena F, David-Neto E, Akalin E, Alani O, Mazzali M, Manfro RC, Bauer AC, Wang AX, Cheng XS, Schold JD, Berger SP, Cravedi P, Riella LV
167. Aldosterone Is Positively Associated With Circulating FGF23 Levels in Chronic Kidney Disease Across Four Species, and May Drive FGF23 Secretion Directly. Front Physiol. 2021,12:649921 (IF )
Radloff J, Pagitz M, Andrukhova O, Oberbauer R, Burgener IA, Erben RG
166. Randomized Trial of Etelcalcetide for Cardiac Hypertrophy in Hemodialysis. Circ Res . 2021, 128(11):1616-1625 (IF )
Dörr K, Kammer M, Reindl-Schwaighofer R, Lorenz M, Prikoszovich T, Marculescu R, Beitzke D, Wielandner A, Erben RG, Oberbauer R.
165. A Prospective Controlled Trial to Evaluate Safety and Efficacy of in vitro Expanded Recipient Regulatory T Cell Therapy and Tocilizumab Together With Donor Bone Marrow Infusion in HLA-Mismatched Living Donor Kidney Transplant Recipients (Trex001). Front Med (Lausanne) 2021, 7:634260
Oberbauer R, Edinger M, Berlakovich G, Kalhs P, Worel N, Heinze G, Wolzt M, Lion T, Wekerle T.
164. Long-term risks after kidney donation: How do we inform potential donors? A survey from descartes and EKITA transplantation working groups. Nephrol Dial Transplant. 2021, 36(9):1742-1753 (IF 4.8)
Mjøen G, Maggiore U, Kessaris N, Kimenai D, Watschinger B, Mariat C, Sever MS, Crespo M, Peruzzi L, Spasovski G, Sørensen SS, Heemann U, Pascual J, Viklicky O, Courtney AE, Hadaya K, Wagner L, Nistor I, Hadjianastassiou V, Durlik M, Helanterä I, Oberbauer R, Oniscu G, Hilbrands L, Abramowicz D; European Renal Association-European Dialysis Transplant Association (ERA-EDTA) Developing Education Science and Care for Renal Transplantation in European States (DESCARTES) working group and the European Society of Organ Transplantation (ESOT) European Kidney Transplant Association (EKITA).
163. Impact of Timely Public Health Measures on Kidney Transplantation in Austria during the SARS-CoV-2 Outbreak-A Nationwide Analysis. J Clin Med. 2020, 9(11):E3465
Watschinger B, Watschinger C, Reindl-Schwaighofer R, Meyer EL, Deak AT, Hammer T, Eigner M, Sprenger-Mähr H, Schneeberger S, Cejka D, Mayer G, Oberbauer R, Rosenkranz AR, Kerschbaum J
162. Cardiac magnetic resonance-derived fibrosis, strain and molecular biomarkers of fibrosis in hypertensive heart disease. J Hypertens. 2020;38(10):2036-2042 (IF )
Pichler G, Redon J, Martínez F, Solaz E, Calaforra O, Andrés MS, Lopez B, Díez J, Oberbauer R, Adlbrecht C, Karth GD, Maceira A.
161. Trajectories of glomerular filtration rate and progression to end stage kidney disease after kidney transplantation. Kidney Int. 2021, 99(1):186-197 (IF 14.8)
Raynaud M, Aubert O, Reese PP, Bouatou Y, Naesens M, Kamar N, Bailly É, Giral M, Ladrière M, Le Quintrec M, Delahousse M, Juric I, Basic-Jukic N, Gupta G, Akalin E, Chin CS, Proust-Lima C, Böhmig G, Oberbauer R, Stegall MD, Bentall AJ, Jordan SC, Huang E, Glotz D, Legendre C, Montgomery RA, Segev DL, Empana JP, Grams ME, Coresh J, Jouven X, Lefaucheur C, Loupy A.
160. High-activity Classical and Alternative Complement Pathway Genotypes—Association With Donor-specific Antibody-triggered Injury and Renal Allograft Survival. Transplantation Direct 2020, 6 (3):e534
Mező B, Reindl-Schwaighofer R, Eskandary F, Heinzel A, Wahrmann M, Doberer K, Heilos A, Bond G, Kläger J, Kozakowski N, Haslacher H, Oberbauer R, Viklický O, Hrubá P, Halloran PF, Rusai K, Prohászka Z, Böhmig GA
159. Renoprotective and Immunomodulatory Effects of GDF15 following AKI Invoked by Ischemia-Reperfusion Injury. J Am Soc Nephrol. 2020, 31(4):701-715 (IF 10.3)
Liu J, Kumar S, Heinzel A, Gao M, Guo J, Alvarado GF, Reindl-Schwaighofer R, Krautzberger AM, Cippà PE, McMahon J, Oberbauer R, McMahon AP
158. Predicting donor, recipient and graft survival inliving donor kidney transplantation to inform pretransplant counselling: the donor and recipient linked iPREDICTLIVING tool – a retrospective study. Transplant Int 2020, 33(7):729-739 (IF 2.7)
Haller MC, Wallisch C, Mjøen G, Holdaas H, Dunkler D, Heinze G, Oberbauer R
157. Effect of etelcalcetide on cardiac hypertrophy in hemodialysis patients: a randomized controlled trial (ETECAR-HD). Trials 2019, 20(1):601 (IF 2)
Dörr K, Kammer M, Reindl-Schwaighofer R, Lorenz M, Loewe C, Marculescu R, Erben R,
Oberbauer R.
156. Integrative analysis of prognostic biomarkers derived from multiomics panels helps discrimination of chronic kidney disease trajectories in people with type 2 diabetes. Kidney Int. 2019, 96(6):1381-1388. (IF 14.8)
Kammer M, Heinzel A, Willency JA, Duffin KL, Mayer G, Simons K, Gerl MJ, Klose C, Heinze G, Reindl-Schwaighofer R, Hu K, Perco P, Eder S, Rosivall L, Mark PB, Ju W, Kretzler M, McCarthy MI, Heerspink HL, Wiecek A, Gomez MF, Oberbauer R; for the BEAt-DKD Consortium
155. Next generation sequencing based assessment of the alloreactive T cell receptor repertoire in kidney transplant patients during rejection: a prospective cohort study. BMC Nephrol. 2019, 20(1):346 (IF 2.2)
Aschauer C, Jelencsics K, Hu K, Heinzel A, Vetter J, Fraunhofer T, Schaller S, Winkler S, Pimenov L, Gualdoni GA, Eder M, Kainz A, Regele H, Reindl-Schwaighofer R, Oberbauer R.
154. Genomic Mismatch at LIMS1 Locus and Kidney Allograft Rejection (letter). N Engl J Med. 2019, 381(9):e16
Reindl-Schwaighofer R, Heinzel A, Oberbauer R
153. The impact of donor and recipient common clinical and genetic variation on estimated glomerular filtration rate in a European renal transplant population. Am J Transplant 2019, 19(8):2262-2273 (IF 8.9)
Stapleton CP, Heinzel A, Guan W, van der Most PJ, van Setten J, Lord GM, Keating BJ, Israni AK, de Borst MH, Bakker SJL, Snieder H, Weale ME, Delaney F, Hernandez-Fuentes MP, Reindl-Schwaighofer R, Oberbauer R, Jacobson PA, Mark PB, Chapman FA, Phelan PJ, Kennedy C, Sexton D, Murray S, Jardine A, Traynor JP, McKnight AJ, Maxwell AP, Smyth LJ, Oetting WS, Matas AJ, Mannon RB, Schladt DP, Iklé DN, Cavalleri GL, Conlon PJ; UK Ireland Renal Transplant Consortium; DeKAF Genomics and GEN03 Studies; International Genetics and Translational Research in Transplantation Network
152. Contribution of genome-wide non-HLA incompatibility between donor and recipient to kidney allograft survival. Lancet 2019, 393(10174):910-917 (IF 98.4)
Reindl-Schwaighofer R, Heinzel A, Kainz A, van Setten J, Jelencsics K, Hu K, Loza B-L, Kammer M, Heinze G, Hruba P, Koňaříková A, Viklicky O, Boehmig GA, Eskandary F, Fischer G, Claas F, Tan JC, Albert TJ, Patel J, Keating B, Oberbauer R, for the iGeneTRAiN consortium
151. Standard work-up of the low-risk kidney transplant candidate: a European expert survey of the ERA-EDTA Developing Education Science and Care for Renal Transplantation in European States Working Group. Nephrol Dial Transplant. 2019, 34(9):1605-1611 (IF 4.8)
Maggiore U, Abramowicz D, Budde K, Crespo M, Mariat C, Oberbauer R, Pascual J, Peruzzi L, Schwartz Sorensen S, Viklicky O, Watschinger B, Oniscu GC, Heemann U, Hilbrands LB
150. Steroid pretreatment of organ donors does not impact on early rejection and long-term kidney allograft survival: Results from a multicenter randomized, controlled trial. Am J Transplant. 2019, 1770-1776. (IF 8.9)
Reindl-Schwaighofer R, Kainz A, Jelencsics K, Heinzel A, Berlakovich G, Remport Á, Heinze G, Langer R, Oberbauer R
149. A randomized controlled trial of alanyl-glutamine supplementation in peritoneal dialysis fluid to assess impact on biomarkers of peritoneal health. Kidney Int. 2018, 94(6):1227-1237 (IF 14.8)
Vychytil A, Herzog R, Probst P, Ribitsch W, Lhotta K, Machold-Fabrizii V, Wiesholzer M, Kaufmann M, Salmhofer H, Windpessl M, Rosenkranz AR, Oberbauer R, König F, Kratochwill K, Aufricht C.
148. Validation of Plasma Biomarker Candidates for the Prediction of eGFR Decline in Patients With Type 2 Diabetes. Diabetes Care 2018, 41(9):1947-1954 (IF 14.8)
Heinzel A, Kammer M, Mayer G, Reindl-Schwaighofer R, Hu K, Perco P, Eder S, Rosivall L, Mark PB, Ju W, Kretzler M, Gilmour P, Wilson JM, Duffin KL, Abdalla M, McCarthy MI, Heinze G, Heerspink HL, Wiecek A, Gomez MF, Oberbauer R; BEAt-DKD Consortium
147. Allograft and patient survival after sequential HSCT and kidney transplantation from the same donor- a multicenter analysis. Am J Transplant 2019, 19(2):475-487 (IF 8.9)
Eder M, Schwarz C, Kammer M, Jacobsen N, Masouridi Levrat S, Cowan MJ, Chongkrairatanakul T, Gaston R, Ravanan R, Ishida H, Bachmann A, Alvarez S, Koch M, Garrouste C, Duffner UA, Cullis B, Schaap N, Medinger M, Sørensen SS, Dauber EM, Böhmig G, Regele H, Berlakovich GA, Wekerle T, Oberbauer R.
146. Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation. J Am Soc Nephrol 2018, 29 (7):1979-1991 (IF 10.3)
Pascual J, Berger SP, Witzke O, Tedesco H, Mulgaonkar S, Qazi Y, Chadban S, Oppenheimer F, Sommerer C, Oberbauer R, Watarai Y, Legendre C, Citterio F, Henry M, Srinivas TR, Luo WL, Marti A, Bernhardt P, Vincenti F; TRANSFORM Investigators
145. NPHP1 (Nephrocystin-1) Gene Deletions Cause Adult-Onset ESRD. J Am Soc Nephrol 2018, 29(6):1772-1779 (IF 10.3)
Snoek R, van Setten J, Keating BJ, Israni AK, Jacobson PA, Oetting WS, Matas AJ, Mannon RB, Zhang Z, Zhang W, Hao K, Murphy B, Reindl-Schwaighofer R, Heinzl A, Oberbauer R, Viklicky O, Conlon PJ, Stapleton CP, Bakker SJL, Snieder H, Peters EDJ, van der Zwaag B, Knoers NVAM, de Borst MH, van Eerde AM
144. Regression of left atrial diameter after kidney transplantation is associated with prolonged survival: an observational study. Transpl Int 2018, 31: 999–1007 (IF 2.7)
Regele F, Kainz A, Kammer M, Beer A, Steringer-Mascherbauer M, Binder T, Oberbauer R
143. Establishing a Core Outcome Measure for Graft Health: a Standardized Outcomes in Nephrology – Kidney Transplantation (SONG-Tx) Consensus Workshop Report. Transplantation 2018, 102(8):1358-1366 (IF 5.3)
Tong A, Sautenet B, Poggio ED, Lentine KL, Oberbauer R, Mannon R, Murphy B, Padilla B, Chow KM, Marson L, Chadban S, Craig JC, Ju A, Manera KE, Hanson CS, Josephson MA, Knoll G, SONG-Tx Graft Health Workshop Investigators
142. Functional Fc gamma receptor gene polymorphisms and donor-specific antibody-triggered microcirculation inflammation. Am J Transplant 2018, 18(9):2261-2273 (IF 8.9)
Arnold M, Kainz A, Hidalgo L, Eskandary F, Kozakowski N, Wahrmann M, Haslacher H, Oberbauer R, Heilos A, Spriewald B, Halloran P, Böhmig G
141. A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection. J Am Soc Nephrol. 2018, 29(2):591-605 (IF 10.3)
Eskandary F, Regele H, Baumann L, Bond G, Kozakowski N, Wahrmann M, Hidalgo LG, Haslacher H, Kaltenecker CC, Aretin MB, Oberbauer R, Posch M, Staudenherz A, Handisurya A, Reeve J, Halloran PF, Böhmig GA.
140. ADHERE: randomized controlled trial comparing renal function in de novo kidney transplant recipients receiving prolonged-release tacrolimus plus mycophenolate mofetil or sirolimus. Transpl Int. 2017, 30(1):83-95. (IF 2.7)
Rummo OO, Carmellini M, Rostaing L, Oberbauer R, Christiaans MH, Mousson C, Langer RM, Citterio F, Charpentier B, Brown M, Kazeem G, Lehner F; ADHERE study investigators
139. Survival analysis of conservative vs. dialysis treatment of elderly patients with CKD stage 5. PLOS ONE 2017, 12(7):e0181345 (IF 2.9)
Reindl-Schwaighofer R, Kainz A, Kammer M, Dumfarth A, Oberbauer R
138. Diffuse Extent of Peritubular Capillaritis in Late Antibody-mediated Rejection: Associations With Levels of Donor-specific Antibodies and Chronic Allograft Injury. Transplantation 2017, 101(5):e178-e187 (IF 5.3)
Kozakowski N1, Eskandary F, Herkner H, Bond G, Oberbauer R, Regele H, Böhmig GA, Kikić Ž
137. Developing consensus-based priority outcome domains for trials in kidney transplantation: a multinational Delphi survey with patients, caregivers and health professionals. Transplantation 2017, 101(8):1875-1886 (IF 5.3)
Sautenet B, Tong A, Manera KE, Chapman JR, Warrens AN, Rosenbloom D, Wong G, Gill J, Budde K, Rostaing L, Marson L, Josephson MA, Reese PP, Pruett TL, Hanson CS, O’Donoghue D, Tam-Tham H, Halimi JM, Shen JI, Kanellis J, Scandling JD, Howard K, Howell M, Cross N, Evangelidis N, Masson P, Oberbauer R, Fung S, Jesudason S, Knight S, Mandayam S, McDonald S, Chadban S, Rajan T, Craig JC
136. Positioning of tacrolimus for the treatment of diabetic nephropathy based on computational network analysis. Plos One 2017, 12(1):e0169518 (IF 2.9)
Aschauer C, Perco P, Heinzel A, Sunzenauer J, Oberbauer R
135. Steroid withdrawal after renal transplantation: a retrospective cohort study. BMC Med. 2017 Jan 12;15(1):8 (IF 7)
Haller M, Kammer M, Kainz A, Bear HJ, Heinze G, Oberbauer R
134. Systems biology derived biomarkers to predict progression of renal function decline in type 2 diabetes mellitus. Diabetes Care 2017, 40(3):391-397 (IF 14.8)
Mayer G, Heerspink HL, Aschauer C, Heinzel A, Heinze G, Kainz A, Sunzenauer J, Perco P, de Zeeuw D, Rossing P, Pena M, Oberbauer R
133. Dialysis Vintage and Outcomes after Kidney Transplantation: A Retrospective Cohort Study. CJASN 2017 12(1):122-130 (IF 8.5)
Haller M, Kainz A, Baer H, Oberbauer R
132. Prognostic value of bone- and vascular derived molecular biomarkers in hemodialysis and renal transplant patients: a systematic review and meta-analysis. Nephrol Dial Transplant 2017;32(9):1566-1578 (IF 4.8)
Pichler G, Haller MC, Kainz A, Wolf M, Redon J, Oberbauer R
131. miR-182-5p Inhibition Ameliorates Ischemic Acute Kidney Injury. Am J Pathol 2017, 187(1):70-79 (IF 6)
Wilflingseder J, Jelencsics K, Bergmeister H, Sunzenauer J, Regele H, Eskandary F, Reindl-Schwaighofer R, Kainz A, Oberbauer R
130. Diagnostic Contribution of Donor-Specific Antibody Characteristics to Uncover Late Silent Antibody-Mediated Rejection-Results of a Cross-Sectional Screening Study. Transplantation 2017, 101(3):631-641 (IF 5.3)
Eskandary F, Bond G, Kozakowski N, Regele H, Marinova L, Wahrmann M, Kikić Ž, Haslacher H, Rasoul-Rockenschaub S, Kaltenecker CC, König F, Hidalgo LG, Oberbauer R, Halloran PF, Böhmig GA
129. Population Attributable Fractions of Modifiable Lifestyle Factors for Chronic Kidney Disease and Mortality in Individuals with Type 2 Diabetes: A Cohort Study. AJKD 2016, 68(1):29-40 (IF 9.4)
Dunkler D, Kohl M, Teo KK, Heinze G, Dehghan M, Clase CC, Gao P, Yusuf S, Mann JFE, Oberbauer R for the ONTARGET Investigators
128. Immune repertoire profiling reveals that clonally expanded B and T cells infiltrating diseased human kidneys can also be tracked in blood. PlosOne 2015; 10(11): e0143125 (IF 2.9)
Weinberger J, Jimenez-Heredia R, Schaller S, Suessner S, Sunzenauer J, Reindl-Schwaighofer R, Weiss R, Winkler S, Gabriel C, Danzer M, Oberbauer R
127. Design and Implementation of the International Genetics and Translational Research in Transplantation Network. Transplantation 2015, 99(11):2401-12 (IF 5.3)
The International Genetics & Translational Research in Transplantation Network (iGeneTRAiN)
126. Chances and challenges of using routine data collections for renal health care research. NDT 2015, 30 (suppl 4): iv68-iv75. (IF 4.8)
Heinze G, Wallisch C, Kainz A, Hronsky M, Leffondre K, Oberbauer R, Mayer G
125. Dietary risk factors for incidence of progression of chronic kidney disease in individuals with type 2 diabetes in the European Union. NDT 2015, 30 (suppl 4): iv76-iv85. (IF 4.8)
Dunkler D, Kohl M, Teo KK, Heinze G, Dehghan M, Clase CM, Gao P, Yusuf S, Mann JFE, Oberbauer R
124. Risk Prediction of Early Chronic Kidney Disease: Net Benefit in Individuals with Type 2 Diabetes. CJASN 2015, 10(8):1371-1379 (IF 8.5)
Dunkler D, Clase C, Gerstein H, Lee SF, Heinze G, Kohl M, Mann JFE, Teo KK, Yusuf S, Oberbauer R, on behalf of the ONTARGET & ORIGIN Investigators.
123. ImmunExplorer (IMEX): A Software Framework for Diversity and Clonality Analyses of Immunoglobulins and T Cell Receptors on the Basis of IMGT / HighV-QUEST Preprocessed NGS Data. BMC Bioinformatics 2015, 16:252. (IF 4.4)
Schaller S, Weinberger J, Jimenez-Heredia R, Danzer M, Oberbauer R, Gabriel C, Winkler SM
122. Molecular diagnostics identifies risks for graft dysfunction despite borderline histologic changes. Kidney Int 2015, 88(4):785-95 (IF 14.8)
Hruba P, Brabcova I, Gueler F, Krejcik Z, Stranecky V, Svobodova E, Maluskova J, Gwinner W, Honsova E, Lodererova A, Oberbauer R, Zachoval R, Viklicky O
121. Effect of combined treatment with immunoadsorption and membrane filtration on plasma coagulation-Results of a randomized controlled crossover study. J Clin Apher 2015, 31(1):29-37
Biesenbach P, Eskandary F, Ay C, Wiegele M, Derfler K, Schaden E, Haslacher H, Oberbauer R, Böhmig GA
120. Capillary C4d Predicts Kidney Allograft Outcome Independently of Morphological Lesions Suggestive of Antibody-Mediated Rejection.CJASN 2015, 10(8):1435-43 (IF 8.5)
Kikić Ž, Kainz A, Kozakowski N, Oberbauer R, Regele H, Bond G, Böhmig GA
119. Modifiable Lifestyle and Social Factors and Chronic Kidney Disease in High-Risk Individuals with Type 2 Diabetes Mellitus. Kidney Int. 2015, 87(4):784-91 (IF 14.8)
Dunkler D, Kohl M, Heinze G, Teo KK, Rosengren A, Pogue J, Gao P, Gerstein H, Yusuf S, Oberbauer R, Mann JFE, for the ONTARGET Investigators
118. From molecular signatures to predictive biomarkers: Modeling disease pathophysiology and drug mechanism of action. Front Cell Dev Biol 2014, 2:37
Heinzel A, Perco P, Mayer G, Oberbauer R, Lukas A, Mayer B
117. Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial. Trials 2014, 15:107-115. (IF 2)
Eskandary F, Bond G, Schwaiger E, Kikic Z, Winzer C, Wahrmann M, Marinova L, Haslacher H, Regele H, Oberbauer R, Böhmig GA
116. A gene variant in CERS2 is associated with rate of increase in albuminuria in patients with diabetes from ONTARGET and TRANSCEND. PLOS ONE 2014; 9(9): e106631. (IF 2.9)
Shiffman D, Paré G, Oberbauer R, Louie JZ, Rowland CM, Devlin JJ, Mann JF, McQueen MJ.
115. Molecular pathogeneses of post-transplant Acute Kidney Injury: assessment of whole-genome mRNA and miRNA profiles. PLOS ONE 2014; 9(8): e104164. (IF 2.9)
Wilflingseder J, Sunzenauer J, Toronyi E, Heinzel A, Kainz A, Mayer B, Perco P, Telkes G, Langer RM, Oberbauer R.
114. Left atrial diameter and survival among renal allograft recipients. CJASN 2013; 8:2100-2105. (IF 8.5)
Kainz A, Goliasch, G, Wiesbauer F, Binder T, Maurer G, Nesser H-J, Mascherbauer R, Ebner C, Kramar R, Wilflingseder J, Oberbauer R.
113. Treatment with Oral Active Vitamin D Is Associated with Decreased Risk of Peritonitis and Improved Survival in Patients on Peritoneal Dialysis. PLOS ONE 2013; 8(7): e67836. (IF 2.9)
Kerschbaum J, Vychytil A, Lhotta K, Prischl FC, Wiesholzer M, Machhold-Fabrizii V, Kopriva-Altfahrt G, Schwarz C, Balcke P, Oberbauer R, Kramar R, König P, Rudnicki M
112. Diet and Kidney Disease in High Risk Individuals with Type 2 Diabetes. JAMA Int Med 2013;173(18):1682-1692. (IF 22.5)
Dunkler D, Dehghan M, Teo KK, Heinze G, Gao P, Kohl M, Clase CM, Mann JFE, Yusuf S, Oberbauer R.
111. miRNA Profiling Discriminates Types of Rejection and Injury in Human Renal Allografts. Transplantation 2013; 95(6):835-41. (IF 5.3)
Wilflingseder J, Regele H, Perco P, Kainz A, Soleiman A, Mühlbacher MD, Mayer B, Oberbauer R.
110. Synthetic lethality for linking Mycophenolate Mofetil mode of action with molecular disease and drug profiles. Mol Biosyst. 2012; 8(12):3197-3207. (IF 3.336)
Söllner J, Mayer P, Heinzel A, Fechete R, Siehs C, Oberbauer R, Mayer B.
109. Sirolimus induced phosphaturia is not caused by inhibition of renal apical sodium phosphate cotransporters. PLOS ONE 2012;7(7):e39229. (IF 2.9)
Haller M, Amatschek S, Wilflingseder J, Kainz A, Bielesz B, Pavik I, Serra A, Mohebbi N, Biber J, Wagner CA, Oberbauer R.
108. Molecular pathways and crosstalk characterizing the cardiorenal syndrome. OMICS 2012; 16(3):105-112. (IF 3.3)
Mühlberger I, Mönks K, Fechete R, Mayer G, Oberbauer R, Mayer B, Perco P.
107. Data graphs for linking clinical phenotype and molecular feature space. IJSBBT 2012; 1(1):11-25.
Heinzel A, Fechete R, Söllner J, Perco P, Heinze G, Oberbauer R, Mayer G, Lukas A, Mayer B.
106. Hemoglobin variability after renal transplantation is associated with mortality. Transpl Int 2012; 25(3):323-327. (IF 2.7)
Kainz A, Wilflingseder J, Függer R, Kramar R, Oberbauer R.
105. The effect of steroid pretreatment of deceased organ donors on liver allograft function: a blinded randomized placebo controlled trial. J Hepatol 2012; 56(6):1305-1309. (IF 26.8)
Amatschek S, Wilflingseder J, Pones M, Kainz A, Bodingbauer M, Mühlbacher F, Langer RM, Gerlei Z, Oberbauer R.
104. The case: hemolysis and acute renal failure. Babesiosis. Kidney Int 2011; 80(6):681-683. (IF 14.8)
Blum S, Gattringer R, Haschke E, Walochnik J, Tschurtschenthaler G, Lang F, Oberbauer R.
103. Effect of intraportal infusion of tacrolimus on ischaemic reperfusion injury in orthotopic liver transplantation: a randomized controlled trial. Transpl Int. 2011; 24(9):912-219. (IF 2.7)
Kristo I, Wilflingseder J, Kainz A, Marschalek J, Wekerle T, Mühlbacher F, Oberbauer R, Bodingbauer M.
102. Mapping of molecular pathways, biomarkers and drug targets for diabetic nephropathy. Proteomics Clin Appl. 2011 Jun;5(5-6):354-366. (IF 2.1)
Fechete R, Heinzel A, Perco P, Mönks K, Söllner J, Stelzer G, Eder S, Lancet D, Oberbauer R, Mayer G, Mayer B.
101. Linking molecular feature space and disease terms for the immunosuppressive drug rapamycin. Mol Biosyst 2011; 7(10):2863-2871. (IF 3.336)
Bernthaler A, Mönks K, Mühlberger I, Mayer B, Perco P, Oberbauer R.
100. The Effect of Fluid Intake on Chronic Kidney Transplant Failure-A Pilot Study. Jour Ren Nutr 2011; 21(6):499-505. (IF 3.4)
Magpantay L, Ziai F, Oberbauer R, Haas M.
99. Cost-effectiveness analysis of renal replacement therapy in Austria. Nephrol Dial Transplant 2011; 26(9):2988-2995. (IF 4.8)
Haller M, Gutjahr G, Kramar R, Harnoncourt F, Oberbauer R.
98. Integrative Bioinformatics Analysis of Proteins Associated with the Cardiorenal Syndrome. Int J Nephrol 2011; 2011:id809378
Mühlberger I, Moenks K, Bernthaler A, Jandrasits C, Mayer B, Mayer G, Oberbauer R, Perco P.
97. Steroid Pretreatment of Organ Donors to Prevent Postischemic Renal Allograft Failure. A Randomized, Controlled Trial. Ann Int Med 2010; 153:222-230. (IF 19.6)
Kainz A, Wilflingseder J, Mitterbauer C, Haller M, Burghuber C, Perco P, Langer RM, Heinze G, Oberbauer R.
96. Molecular biomarker candidates of acute kidney injury in zero-hour renal transplant needle biopsies. Transpl Int 2011;24(2):143-149 (IF 2.7)
Korbély R, Wilflingseder J, Perco P, Kainz A, Langer RM, Mayer B, Oberbauer R.
95. Association of ESA hypo-responsiveness and haemoglobin variablility with mortality in haemodialysis patients. Nephrol Dial Transplant 2010; 25:3701-3706. (IF 4.8)
Kainz A, Mayer B, Kramar R, Oberbauer R.
94. Linking transcriptomics and proteomics data on the level of protein interaction networks. Electrophoresis 2010; 31:1780-1789. (IF 3)
Perco P, Mühlberger I, Mayer G, Oberbauer R, Lukas A, Mayer B.
93. Impaired metabolism in donor kidney grafts after steroid pretreatment. Transpl Int 2010; 23:796-804. (IF 2.7)
Wilflingseder J, Kainz A, Mühlberger I, Perco P, Langer R, Kristo I, Mayer B, Oberbauer R.
92. Sirolimus in renal transplant recipients with tuberous sclerosis complex: clinical effectiveness and implications for innate immunity. Transpl Int 2010; 23:777-785. (IF 2.7)
Haidinger M, Hecking M, Weichhart T, Poglitsch M, Enkner W, Vonbank K, Prayer D, Geusau A, Oberbauer R, Zlabinger GJ, Soleiman A, Hörl WH., Säemann MD.
91. Glucose control is associated with patient survival in diabetic patients after renal transplantation. Transplantation 2010; 89:612-619. (IF 5.3)
Wiesbauer F, Heinze G, Regele H, Hörl WH, Schernthaner GH, Schwarz C, Kainz A, Kramar R, Oberbauer R.
90. Biocompatibility of Peritoneal Dialysis Solutions Determined by Genomics of Human Leukocytes: A Cross-over study. Nephrol Dial Transplant plus 2009; 2:510-512
Wilflingseder J, Kainz A, Perco P, Mayer B, Oberbauer R.
89. Non-persistent effect of short-term bisphosphonate treatment in preventing fractures after liver transplantation. Transpl Int 2010; 23:118-120. (IF 2.7)
Bodingbauer M, Pakrah B, Kristo I, Marschalek J, Burghuber C, Györi G, Kainz A, Rasoul-Rockenschaub S, Klaushofer K, Muehlbacher F, Oberbauer R.
88. Hemoglobin levels above 12.5 g/dl achieved by erythropoietin stimulating agents in renal transplant recipients are associated with elevated mortality: a cohort study. BMJ 2009; 339:b4018. (IF 93.6)
Heinze G, Kainz A, Hörl WH, Oberbauer R.
87. Antithymocyte globulin use for treatment of biopsy confirmed acute rejection is associated with prolonged renal allograft survival. Transpl Int 2010; 23:64-70. (IF 2.7)
Kainz A, Korbely R, Soleiman A, Mayer B, Oberbauer R.
86. Mycophenolate Mofetil use is associated with prolonged graft survival after kidney transplantation. Transplantation 2009; 88:1095-1100. (IF 5.3)
Kainz A, Heinze G, Korbely R, Schwarz C, Oberbauer R.
85. Calcineurin inhibitor based immunosuppressive therapy, donor age and long term outcome after kidney transplantation. Transplantation 2009; 87:1821-1829. (IF 5.3)
Heinze G, Oberbauer R, Kainz A, Mitterbauer C, Koppelstaetter C, Hörl WH, Mayer G.
84. Body mass index modifies the risk of cardiovascular death in proteinuric chronic kidney disease. Nephrol Dial Transplant 2009; 24: 2421-2428. (IF 4.8)
Obermayr R, Temml C, Gutjahr G, Kainz A, Klauser-Braun R, Fuegger R, Oberbauer R.
83. Conversion From Calcineurin Inhibitors to Sirolimus Maintenance Therapy in Renal Allograft Recipients: 24-Month Efficacy and Safety Results From the CONVERT Trial. Transplantation 2009; 87:233-242. (IF 5.3)
Schena FP, Pascoe MD, Alberu J, Del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF; for the Sirolimus CONVERT Trial Study Group.
82. Microarray and bioinformatic analysis of gene expression in experimental membranous nephropathy. Nephron Exp Nephrol 2009; 112:43-58. (IF 2.238)
Hauser PV, Perco P, Muehlberger I, Pippin J, Blonski M, Mayer B, Alpers C, Oberbauer R, Shankland SJ.
81. Hypoxia response and VEGF-A expression in human proximal tubular epithelial cells in stable and progressive renal disease. Lab Invest 2009, 89:337-346. (IF 5.1)
Rudnicki M, Perco P, Enrich J, Eder S, Heininger D, Bernthaler A, Wiesinger M, Sarközi R, Noppert SJ, Schramek H, Mayer B, Oberbauer R, Mayer G.
80. Molecular predictors for anaemia after kidney transplantation. Nephrol Dial Transplant 2009, 24:1015-1023. (IF 4.8)
Wilflingseder J, Kainz A, Perco P, Korbely R, Mayer B, Oberbauer R.
79. Histogenomics: Association of gene expression patterns with histological parameters in kidney biopsies. Transplantation 2009, 87:290-295. (IF 5.3)
Perco P, Kainz A, Wilflingseder J, Soleiman A, Mayer B, Oberbauer R.
78. Markers of cellular senescence in zero hour biopsies predict outcome in renal transplantation. Aging Cell 2008, 7:491-497. (IF 8)
Koppelstaetter C, Schratzberger G, Perco P, Hofer J, Mark W, Ollinger R, Oberbauer R, Schwarz C, Mitterbauer C, Kainz A, Karkoszka H, Wiecek A, Mayer B, Mayer G.
77. Biocompatibility of Hemodialysis Membranes Determined by Differential Gene Expression Analysis of Human Leukocytes: A randomized Cross-over Study. Eur J Clin Invest 2008, 38: 918–924 (IF 4.4)
Wilflingseder J, Perco P, Kainz A, Mayer B, Oberbauer R.
76. Short-term effects of high dose zoledronic acid treatment on bone mineralization density distribution (BMDD) after orthotopic liver transplantation. Calcif Tiss Int 2008, 83:167-175. (IF 3.3)
Misof BM, Bodingbauer M, Roschger P, Wekerle T, Pakrah B, Haas M, Kainz A, Oberbauer R, Mühlbacher F, Klaushofer K.
75. Can we really predict the change in serum sodium levels? – An analysis of currently proposed formulae in hypernatremic patients. Nephrol Dial Transplant 2008, 23:3501-3508. (IF 4.8)
Lindner G, Schwarz C, Kneidinger N, Kramer L, Oberbauer R, Druml W.
74. Statin use is associated with prolonged survival of renal transplant recipients. JASN 2008,19:2211-2218. (IF 10.3)
Wiesbauer F, Heinze G, Mitterbauer C, Harnoncourt F, Hörl WH, Oberbauer R.
73. Elevated Uric Acid Increases the Risk for Kidney Disease. JASN 2008, 19:2407-13. (IF 10.3)
Obermayr R, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R.
72. A single nucleotide polymorphism at chromosome 2q21.3 (LCT 13910C>T) associates with clinical outcome after allogeneic hematopoetic stem cell transplantation. Blood 2008, 112:2156-2159. (IF 21)
Hauser H, Zach O, Krieger O, Kasparu H, Koenig J, Girschikofsky M, Oberbauer R, Lutz D.
71. Predictors of new-onset decline in kidney function in a general middle-European population. Nephrol Dial Transplant 2008, 23:1265-1273. (IF 4.8)
Obermayr RP, Temml C, Knechtelsdorfer M, Gutjahr G, Kletzmayr J, Heiss S, Ponholzer A, Madersbacher S, Oberauer R, Klauser-Braun R.
70. ACE-Inhibitor or AT2-Antagonist therapy of renal transplant recipients is associated with an increase in serum potassium concentrations. Nephrol Dial Transplant 2008, 23:1742-1746. (IF 4.8)
Mitterbauer C, Heinze G, Kainz A, Kramar R, Hörl WH, Oberbauer R.
69. Three-year health-related quality-of-life outcomes for sirolimus-treated kidney transplant patients after elimination of cyclosporine. Transpl Int. 2007, 20:875-883. (IF 2.7)
Russ G, Jamieson N, Oberbauer R, Arias M, Murgia MG, Blancho G, Sato R, Stoeckl M, Revicki DA.
68. Incidence of anemia in sirolimus-treated renal transplant recipients: the importance of preserving renal function. Transpl Int 2007, 20:754-760. (IF 2.7)
Friend P, Russ G, Oberbauer R, Murgia MG, Tufveson G, Chapman J, Blancho G, Mota A, Granaliano G, Campistol JM, Brault Y, Burke JT for the Rapamune Maintenance Regimen (RMR) Study Group.
67. Prophylactic Bisphosphonate Treatment Prevents Bone Fractures After Liver Transplantation. Am J Transplant 2007, 7:1763-1769. (IF 8.9)
Bodingbauer M, Wekerle T, Pakrah B, Roschger P, Peck-Radosavljevic M, Silberhumer G, Grampp S, Rockenschaub S, Berlakovich G, Steininger R, Klaushofer K, Oberbauer R, Muhlbacher F.
66. Letter: Does size matter? Nephrol Dial Transplant 2007, 22:2725-2726. — Response to Opelz et al. J Am Soc Nephrol 2006, 17:3257-3262. (IF 4.8)
65. Gene expression profiles and age of donor kidney biopsies obtained before transplantation distinguish medium term graft function. Transplantation 2007, 83:1048-1054. (IF 5.3)
Kainz A, Perco P, Mayer B, Soleiman A, Steininger R, Mayer G, Mitterbauer C, Schwarz C, Meyer TW, Oberbauer R.
64. Age and sex are sufficient for predicting fractures occurring within one year of hemodialysis treatment. Bone 2007, 40:516-521. (IF 3.5)
Mitterbauer C, Kramar R, Oberbauer R.
63. Factors influencing glomerular filtration rate in renal transplantation after cyclosporine withdrawal using sirolimus-based therapy: a multivariate analysis of results at five years. Clin Transpl 2007. (IF 1.9)
Legendre C, Brault Y, Morales JM, Oberbauer R, Altieri P, Riad H, Mahony J, Messina M, Pussell B, Martínez JG, Lelong M, Burke JT, Neylan J for the Rapamune Maintenance Regimen Study Group.
62. Gene expression profiles of human proximal tubular epithelial cells in proteinuric nephropathies. Kidney Int 2007, 71:325-335. (IF 14.8)
Rudnicki M, Eder S, Perco P, Enrich J, Scheiber K, Koppelstätter C, Schratzberger G, Mayer B, Oberbauer R, Meyer TW, Mayer G.
61. The Association between ACE Inhibitor or Angiotensin Receptor Blocker Use during Postischemic Acute Transplant Failure and Renal Allograft Survival. Transplantation 2006, 82:1441-1448. (IF 5.3)
Heinze G, Collins S, Benedict MA, Nguyen LL, Kramar R, Winkelmayer WC, Haas M, Kainz A, Oberbauer R.
60. “Weight-Listing” Paradox for Candidates of Renal Transplantation? Am J Transplant 2007, 7:550-559. (IF 8.9)
Schold JD, Srinivas TR, Guerra G, Reed AI, Johnson RJ, Weiner ID, Oberbauer R, Harman JS, Hemming AW, Meier-Kriesche HU.
59. Complete renal tubular acidosis late after kidney transplantation. Nephrol Dial Transplant 2006, 21:2615-2620. (IF 4.8)
Schwarz C, Benesch T, Kodras K, Oberbauer R, Haas M.
58. Effects of Bisphosphonates on Bone Loss in the First Year after Renal Transplantation: A Metaanalysis of Randomized Controlled Trials. Nephrol Dial Transplant 2006, 21:2275-2281. (IF 4.8)
Mitterbauer C, Schwarz C, Haas M, Oberbauer R.
57. Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity. Wien Klin Wochenschr. 2006, 118(1-2):49-53. (IF 1.9)
Worel N, Schulenburg A, Mitterbauer M, Keil F, Rabitsch W, Kalhs P, Gisslinger H, Raderer M, Geissler K, Hocker P, Zielinski CC, Oberbauer R, Greinix HT.
56. Molecular signature of mice T lymphocytes following tolerance induction by allogeneic BMT and CD40-CD40L costimulation blockade. Transpl Int. 2006, 19:146-157. (IF 2.7)
Perco P, Blaha P, Kainz A, Mayer B, Hauser P, Wekerle T, Oberbauer R.
55. Sirolimus therapy after early cyclosporine withdrawal reduces the risk of cancer in adult renal transplantation. J Am Soc Nephrol 2006, 17:581-589. (IF 10.3)
Campistol JM, Eris J, Oberbauer R, Friend P, Hutchison B, Morales JM, Claesson K, Stallone G, Russ G, Rostaing L, Kreis H, Burke JT, Brault Y, Scarola JA and Neylan JF for the Rapamune Maintenance Regimen (RMR) Study Group.
54. Angiotensin-converting enzyme inhibitor or AT1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 2006, 17:889-899. (IF 10.3)
Heinze G, Mitterbauer C, Regele H, Kramar R, Winkelmayer W, Curhan G, Oberbauer R.
53. Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function. Transplantation 2005, 80:1204-1211. (IF 5.3)
Russ G, Segoloni G, Oberbauer R, Legendre C, Mota A, Eris J, Grinyo JM, Friend P, Lawen J, Hartmann A, Schena FP, Lelong M, Burke JT, Neylan JF; for the Rapamune Maintenance Regimen Study Group.
52. Transcriptional response in the unaffected kidney after contralateral hydronephrosis or nephrectomy. Kidney Int 2005, 68:2497-2507. (IF 14.8)
Hauser P, Kainz A, Perco P, Bergmeister H, Mitterbauer C, Schwarz C, Regele HM, Mayer B, Meyer TW, Oberbauer R.
51. Detection of coregulation in differential gene expression profiles. BioSystems 2005, 82:235-247. (IF 3.336)
Perco P, Kainz A, Mayer G, Lukas A, Oberbauer R, Mayer B.
50. Differential expression of alphaB-crystallin and Hsp27-1 in anaplastic thyroid carcinomas because of tumor-specific alphaB-crystallin gene (CRYAB) silencing. Cell Stress & Chaperones 2005, 10:171-184. (IF 3.3)
Mineva I, Gartner W, Hauser P, Kainz A, Löffler M, Wolf G, Oberbauer R, Weissel M, Wagner L.
49. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transplant Int 2005, 18:22-18. (IF 2.7)
Oberbauer R, Segoloni G, Campistol JM, Kreis H, Mota A, Lawen J, Russ G, Grinyo JM, Stallone G, Hartmann A, Pinto JR, Chapman J, Burke JT, Brault Y, Neylan JF.
48. Alterations in gene expression in cadaveric vs live donor kidneys suggest impaired tubular counterbalance of oxidative stress at implantation. Am J Transplant 2004, 4:1595-1604. (IF 8.9)
Kainz A, Mitterbauer C, Hauser P, Schwarz C, Regele HM, Berlakovich G, Mayer G, Perco P, Mayer B, Meyer TW and Oberbauer R.
47. The effect of ACE inhibitor and angiotensin II blocker therapy on early posttransplant kidney graft function. Am J Kidney Dis 2004, 43:1065-70. (IF 9.4)
Lorenz M, Billensteiner E, Bodingbauer M, Oberbauer R, Hörl WH, Haas M.
46. Sirolimus-based therapy following early cyclosporine withdrawal results in superior renal allograft survival compared with a cotinuous combination of sirolimus and cyclosporine. J Am Soc Nephrol 2004, 15:809-17. (IF 10.3)
Kreis H, Oberbauer R, Campistol JM, Mathew T, Daloze P, Schena FP, Burke JT, Brault Y, Gioud-Paquet M, Scarola JA, Neylan JF, for the RMR Trial.
45. Genome wide gene expression patterns of donor kidney biopsies distinguish primary allograft function. Lab Invest 2004, 84:353-361. (IF 5.1)
Hauser P, Schwarz C, Mitterbauer C, Regele MH, Mühlbacher F, Mayer G, Perco P, Mayer B, Meyer TW and Oberbauer R.
44. Non-Sustained Effect of Short-Term Bisphosphonate Therapy on Bone Turnover Three Years After Renal Transplantation. Kidney Int 2004, 65:304-309. (IF 14.8)
Schwarz C, Mitterbauer C, Heinze G, Woloszczuk W, Haas M, Oberbauer R.
43. Flow Monitoring: Performance Characteristics of Ultrasound Dilution Versus Color Doppler Ultrasound Compared With Fistulography. Am J Kidney Dis 2003, 42:539-545. (IF 9.4)
Schwarz C, Mitterbauer C, Boczula M, Maca T, Funovics M, Heinze G, Lorenz M, Kovarik J, Oberbauer R.
42. Long-term improvement in renal function is shown in patients treated with sirolimus and cyclosporine withdrawal: 2-year results of the rapamune maintenance regimen. Transplantation 2003, 76:364-370. (IF 5.3)
41. Health related quality of life outcomes of sirolimus treated kideny transplant patients after elimination of cyclosporine: results of a two-year randomized clinical trial. Transplantation 2003, 75:1277-1285. (IF 5.3)
40. Impaired tubulointerstitial expression of ET-1 and NOS isoforms in donor kidney biopsies with postischemic acute renal failure. Transplantation 2003, 76:715-720. (IF 5.3)
Mitterbauer C, Schwarz C, Hauser P, Steininger R, Regele HM, Rosenkranz A, Oberbauer R.
39. Body mass index is the main risk factor for arterial hypertension in young subjects without major comorbidity. Europ J Clin Invest 2003, 33:223-230. (IF 4.4)
Lukas A, Kumbein F, Temml C, Mayer B, Oberbauer R.
38. The influence of comorbidity on the effect of levofloxacin treatment success of ambulatory respiratory tract infections. WMW 2003, 7/8:156-162. (IF 1.1)
Burgmann H, Mayer B, Lukas A, Kumbein F, Oberbauer R.
37. Zoledronic acid to prevent bone loss in the first six months after renal transplantation. Kidney Int 2003, 63:1130-1136. (IF 14.8)
Haas M, Leko-Mohr Z, Roschger P, Kletzmayr J, Schwarz C, Mitterbauer C, Steininger R, Grampp S, Klaushofer K, Delling G, Oberbauer R.
36. Olfactory function in chronic renal failure. American Journal of Rhinology 2002, 16:275-9. (IF 1.553)
Frasnelli J, Temmel AFP, Quint C, Oberbauer R, Hummel T.
35. Failure of Bcl-2 upregulation in proximal tubular epithelial cells of donor kidney biopsies is associated with apoptosis and delayed graft function. Lab Invest 2002, 82:941-948. (IF 5.1)
Schwarz C, Hauser P, Steininger R, Regele H, Heinze G, Mayer G, Oberbauer R.
34. Effects of AT1 and AT2 receptor blockade on angiotensin II induced apoptosis of human renal proximal tubular epithelial cells. Middle Europ J Med 2002, 114/15-16:725-729. (IF 0.116)
Weidekamm C, Hauser P, Hansmann C, Schwarz C, Klingler HC, Mayer G, Oberbauer R.
33. Pimecrolimus: an ascomycin macrolactam derivate for the oral treatment of psoriasis efficacy, safety, pharmacokinetics and pharmacogenetics. J Invest Dermatol 2002, 119:876-87. (IF 5.7)
Rappersberger C, Komar M, Ebelin ME, Scott G, Burtin P, Greig G, Kehren J, Chibout SD, Holter W, Richter L, Oberbauer R, Cordier A, Stütz A, Wolff K.
32. Osteoprotegerin as Marker of High Turnover Osteodystrophy and Decreased Bone Mineralization in Hemodialysis Patients. Am J Kidney Dis 2002, 39:580-586. (IF 9.4)
Haas M, Leko-Mohr Z, Roschger P, Klaushofer K, Kletzmayr J, Schwarz C, Domenig C, Zsontsich T, Delling G, Oberbauer R.
31. Effects of microinjection of synthetic Bcl-2 family member domain peptides on apoptosis of renal proximal tubular epithelial cells in vivo. Am J Physiol 2002, 283:F190-F196. (IF 3.077)
Peherstorfer E, Mayer B, Böhm S, Lukas A, Mayer G, Oberbauer R.
30. Discrete simulation of regulatory homo- and heterodimerization in the apoptosis effector phase. Bioinformatics 2002, 18:67-76. (IF 4.4)
Siehs C, Oberbauer R, Mayer G, Lukas A, Mayer B.
29. Oxidatively modified serum proteins as mediators of neutrophil stimulation. J Immunol 2001, 167:451-460. (IF 3.6)
Körmöczi GF, Wölfel UM, Rosenkranz AR, Hörl WH, Oberbauer R, Zlabinger GJ.
28. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001, 72:777-786. (IF 5.3)
Johnson RWG, Kreis H, Oberbauer R, Brattström C, Claesson K, Eris J.
27. The long term effect of simultaneous heart and kidney transplantation on native renal function. Transplantation 2001, 71: 1597-1600. (IF 5.3)
Bergler-Klein J, Pirich C, Laufer G, Grimm M, Regele H, Mayer G, Oberbauer R.
26. Apoptosis and cellular proliferation after acute renal failure in rats subjected to uninephrectomy. J Lab Clin Med 2001, 138: 343-351. (IF 2.795)
Oberbauer R, Schwarz C, Regele HM, Hansmann C, Meyer TW, Mayer G.
25. The effect of adhesion molecule expression in donor kidney biopsies on early allograft function. Transplantation 2001, 71: 1666-1670. (IF 5.3)
Schwarz C, Regele H, Steininger R, Hansmann C, Mayer G, Oberbauer R.
24. Reduction in mean glomerular pore size coincides with development of large shunt pores in patients with diabetic nephropathy. Exp Nephrol 2001, 9:49-53. (IF 1.511)
Oberbauer R, Nenov V, Weidekamm C, Haas M, Szekeres T, Mayer G.
23. Impaired renal phosphate handling in renal transplant recipients with rapamycin immunosuppression. Nephrol Dial Transplant 2001, 16: 378-382. (IF 4.8)
Schwarz C, Böhmig GA, Steininger R, Mayer G, Oberbauer R.
22. Effect of anticoagulation on blood membrane interactions during hemodialysis. Kidney Int 1999, 56: 1578-1583. (IF 14.8)
Hofbauer R, Moser D, Frass M, Oberbauer R, Kaye AD, Wagner O, Kapiotis S, Druml W.
21. Apoptosis of tubular epithelial cells in donor kidney biopsies predict early graft function. J Am Soc Nephrol 1999, 10: 2006-2013. (IF 10.3)
Oberbauer R, Rohrmoser M, Regele H, Mühlbacher F, Mayer G.
20. Pharmacodynamics and pharmacokinetics of allopurinol in elderly and young subjects. Br J Clin Pharmacol 1999, 48, 501-509. (IF 3.4)
Turnheim K, Krivanek P, Oberbauer R.
19. Heart transplantation or combined heart/kidney transplantation? – even one renal biopsy may fool you. Nephrol Dial Transplant 1999, 14: 1014-1015. (IF 4.8)
Haas M, Kain R, Mayer G, Oberbauer R.
18. Urinary excretion of apo(a) fragments in IDDM patients. Metabolism 1999, 48: 369-372. (IF 10.8)
Clodi M, Oberbauer R, Bodlaj G, Maurer G, Waldhäusel W, Kostner K.
17. Plasma immunoadsorption treatment in patients with primary focal and segmental glomerulosclerosis. Nephrol Dial Transplant 1998, 13: 2013-2016. (IF 4.8)
Haas M, Godfrin Y, Oberbauer R, Yilmaz N, Borchard K, Regele H, Druml W, Derfler K, Mayer G.
16. The patient developing Wallenberg’s syndrome during plasma separation. Nephrol Dial Transplant 1998, 13: 3261-3262. (IF 4.8)
Haas M, Oberbauer R, Druml W, Derfler K, Görzer H, Schmied M, Mayer G.
15. Urinary apolipoprotein (a) excretion in patients with proteinuria. Ann Med 1998, 30: 497-502. (IF 4.9)
Kostner KM, Banyai S, Banyai M, Maurer G, Hörl WH, Oberbauer R.
14. Acid base disorder during plasma immunoadsorption treatment using citrate anticoagulation. Nephrol Dial Transplant 1998, 13: 1581-1582. (IF 4.8)
Oberbauer R, Fabrizii V, Druml W, Mayer G.
13. Natriuretic effect of adenosie A1-receptor blockade in rats. Nephrol Dial Transplant 1998, 13: 900-903. (IF 4.8)
Oberbauer R, Schreiner GF, Meyer TW.
12. Low dose ACE inhibition and glomerular permselectivity in renal transplant recipients. Kidney Int 1997, 52: 1622-1625. (IF 14.8)
Borchard K, Haas M, Yilmaz N, Oberbauer R, Schmidt A, Barnas U, Mayer G.
11. Urinary excretion of apo(a) fragments in NIDDM patients. Diabetologia 1997, 40: 1455-1460. (IF 8.4)
Clodi M, Oberbauer R, Waldhäusel W, Maurer G, Kostner K.
10. Urinary excretion of apo(a) in patients after kidney transplantation. Nephrol Dial Transplant 1997, 12: 2673-2678. (IF 4.8)
Kostner KM, Oberbauer R, Hoffmann U, Stefenelli T, Maurer G, Watschinger B.
9. Serum tumor markers after renal transplantation. Transplantation 1996, 62: 1506-1509. (IF 5.3)
Oberbauer R, Banyai S, Schmidt A, Kornek G, Scheithauer W, Mayer G.
8. The effects of prolonged angiotensin converting enzyme inhibition on excretory kidney function and proteinuria in renal allograft recipients with chronic progressive transplant failure. Nephrol Dial Transplant 1996, 11:1822-1824. (IF 4.8)
Barnas U, Schmidt A, Haas M, Oberbauer R, Mayer G.
7. In vivo supression of the renal Na+/Pi cotransporter by antisense oligonucleotides. Proc Natl Acad Sci USA 1996, 93: 4903-4906. (IF 9.4)
Oberbauer R, Schreiner GF, Biber J, Murer H, Meyer TW.
6. Atubular Glomeruli in patients with chronic allograft rejection. Transplantation 1996, 61: 1166-1171. (IF 5.3)
Pagtalunan ME, Oberbauer R, Haas M, Barlan M, Mayer G, Olson JL, Meyer TW.
5. The effect of prolonged substitution of recombinant human growth hormone on renal functional reserve in growth hormone deficient adults. J Am Soc Nephrol 1995, 6: 1434-1438. (IF 10.3)
Riedl M, Haas M, Oberbauer R, Giesinger J, Luger A, Mayer G.
4. Renal uptake of an 18-mer phosphorothioate oligonucleotid. Kidney Int 1995, 48: 1226-1232. (IF 14.8)
Oberbauer R, Schreiner GF, Meyer TW.
3. Glomerular Permselectivity in proteinuric patients after kidney transplantation. J Clin Invest 1995, 96: 22-29. (IF 13.3)
Oberbauer R, Haas M, Regele H, Barnas U, Schmidt A, Mayer G.
2. Pharmacokinetics and pharmacodynamics of the diuretic bumetanide in the elderly. Clin Pharmacol Ther 1995, 57: 42-51. (IF 6.3)
Oberbauer R, Krivanek P, Turnheim K.
1. Pharmcokinetics of indomethacin in the elderly. Clin Pharmacokinet 1993, 24: 428-434. (IF 4.6)
Oberbauer R, Krivanek P, Turnheim K.
